CDC20 and prostate carcinoma: SPOP is mutated in up to 15% of prostate cancers [60] and these mutations have been shown to result in an inability of SPOP to associate with CDC20, preventing CDC20 protein turnover and consequently resistance to CDC20 inhibitors [16].